Press release
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) announces that Soni Basi has been appointed Executive Vice President and Chief Human Resources
About this update from Incyte Corporation
[{"type":"text","content":" WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) announces that Soni Basi has been appointed Executive Vice President and Chief Human Resources Officer (CHRO) effective today, August 25, 2025. In her new role, Ms. Basi will serve as a key member of the Executive Leadership Team and be responsible for shaping the Company’s global human resources strategy including talent acquisition, organizational design and professional development.\n\n\n“Soni has extensive knowledge and experience in all aspects of human resources,” said Bill Meury, President and Chief Executive Officer, Incyte. “She is a skilled professional and collaborative leader who will bring a strategic mindset and operational focus to the company. Soni will play a key role in attracting, developing and retaining top talent at Incyte and preparing the organization for the next phase of growth.”\n\n\nWith over 25 years of experience in global HR and business leadership, Ms. Basi is recognized for leading high-performing HR teams and managing organizational transformation. Before joining Incyte, Ms. Basi was CHRO at Edelman where she oversaw a team of 200+ HR professionals. Previously, Ms. Basi held leadership roles in global talent at AIG, Allergan Pharmaceuticals, The Estée Lauder Companies and Schering-Plough. Ms. Basi earned her M.A. and Ph.D. in Social Psychology from Bowling Green State University.\n\n\nMs. Basi succeeds Paula Swain, Incyte’s former Executive Vice President and Head of Human Resources, following her retirement.\n\n\nAbout Incyte\n\n\nA global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.\n\n\nFor additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.\n\n\nForward-Looking Statements\n\n\nExcept for the historical information set forth herein, the matters set forth in this release contain predictions, estimates and other forward-looking statements...